Haemonetics (HAE) Hits New 52-Week High at $114.57

Share on StockTwits

Shares of Haemonetics Co. (NYSE:HAE) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $114.57 and last traded at $114.38, with a volume of 9195 shares trading hands. The stock had previously closed at $112.81.

Several analysts have issued reports on HAE shares. Jefferies Financial Group boosted their target price on Haemonetics from $95.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, June 14th. Zacks Investment Research upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $105.00 price objective on the stock in a research note on Tuesday, June 12th. Barrington Research boosted their price objective on Haemonetics from $90.00 to $118.00 and gave the company an “outperform” rating in a research note on Thursday, August 9th. Morgan Stanley boosted their price objective on Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday, August 8th. Finally, TheStreet lowered Haemonetics from a “b” rating to a “c+” rating in a research note on Monday, August 20th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Haemonetics currently has an average rating of “Buy” and a consensus price target of $98.33.

The company has a debt-to-equity ratio of 0.49, a current ratio of 2.84 and a quick ratio of 1.94. The company has a market cap of $5.75 billion, a PE ratio of 61.20, a price-to-earnings-growth ratio of 3.62 and a beta of 1.01.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Tuesday, August 7th. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.17. Haemonetics had a return on equity of 15.00% and a net margin of 2.45%. The company had revenue of $229.35 million for the quarter, compared to analyst estimates of $219.52 million. equities analysts expect that Haemonetics Co. will post 2.28 EPS for the current year.

In related news, SVP Jacqueline Scanlan sold 4,890 shares of the business’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $112.19, for a total transaction of $548,609.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO William P. Mr. Burke sold 6,687 shares of the business’s stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $92.17, for a total value of $616,340.79. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,770 shares of company stock worth $1,832,916. 1.04% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the stock. Chicago Equity Partners LLC grew its position in Haemonetics by 34.0% during the second quarter. Chicago Equity Partners LLC now owns 86,665 shares of the medical instruments supplier’s stock worth $7,772,000 after buying an additional 22,000 shares in the last quarter. Columbus Circle Investors grew its position in Haemonetics by 30.8% during the second quarter. Columbus Circle Investors now owns 260,678 shares of the medical instruments supplier’s stock worth $23,378,000 after buying an additional 61,375 shares in the last quarter. Boston Partners purchased a new position in Haemonetics during the second quarter worth about $1,794,000. ClariVest Asset Management LLC grew its position in Haemonetics by 621,171.4% during the second quarter. ClariVest Asset Management LLC now owns 43,489 shares of the medical instruments supplier’s stock worth $3,900,000 after buying an additional 43,482 shares in the last quarter. Finally, Swiss National Bank grew its position in Haemonetics by 2.2% during the first quarter. Swiss National Bank now owns 91,600 shares of the medical instruments supplier’s stock worth $6,701,000 after buying an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Haemonetics Company Profile (NYSE:HAE)

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

See Also: Relative Strength Index

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Connect Group  Given “Hold” Rating at Peel Hunt
Connect Group Given “Hold” Rating at Peel Hunt
Imperial Oil Ltd  Shares Sold by AMP Capital Investors Ltd
Imperial Oil Ltd Shares Sold by AMP Capital Investors Ltd
Steel Dynamics  Rating Increased to Buy at Zacks Investment Research
Steel Dynamics Rating Increased to Buy at Zacks Investment Research
Haemonetics  Hits New 52-Week High at $114.57
Haemonetics Hits New 52-Week High at $114.57
Zacks Investment Research Upgrades Synthetic Biologics  to Buy
Zacks Investment Research Upgrades Synthetic Biologics to Buy
Quest Diagnostics  Given a $120.00 Price Target at Argus
Quest Diagnostics Given a $120.00 Price Target at Argus


Leave a Reply

© 2006-2018 Ticker Report. Google+.